What the evidence says about cannabis for multiple sclerosis symptoms | Research

The takeaway

Cannabinoids show some promise for MS-related spasticity and pain, but clinical trial evidence remains limited and most support comes from preclinical or animal studies.

MS patients exploring symptom management options, neurologists, and researchers studying cannabinoid therapeutics.

Up to 80% of MS patients experience disabling symptoms like spasticity and pain

What the researchers found

The endocannabinoid system plays a documented role in demyelination and neuroinflammation. Clinical data, primarily from nabiximols (Sativex), suggests modest benefit for spasticity, but evidence for other MS symptoms is thin.

Why it matters

Up to 80% of people with MS deal with disabling symptoms, and first-line treatments carry significant side effects. Cannabinoids represent an area of active patient interest that needs rigorous clinical evaluation.

The numbers in context

Up to 80% of MS patients experience disabling symptoms. Nabiximols (THC:CBD 1:1 spray) is the most studied cannabinoid product for MS spasticity. Clinical trials remain relatively few compared to the volume of preclinical research.

How the study worked

Narrative review of preclinical studies on cannabinoids in experimental demyelination models and clinical trials examining cannabinoid therapies for MS symptoms including spasticity, pain, and bladder dysfunction.

What this study cannot tell us

Narrative review without systematic methodology. Heavy reliance on animal and preclinical models. Clinical trial data limited primarily to nabiximols. Does not address long-term safety of cannabinoid use in MS populations.

How to read the evidence

Narrative review drawing primarily from preclinical models with limited clinical trial evidence, mostly focused on one product (nabiximols).

When this study was published

Published 2022.

The bigger picture

MS patients are already using cannabis products in large numbers. The gap between patient demand and clinical evidence creates a situation where people are essentially self-experimenting without reliable dosing or formulation guidance.

Questions still open

Which specific cannabinoid formulations and ratios would be most effective for different MS symptoms? Could cannabinoids modify disease progression, not just symptoms?

Common questions

Does cannabis help with MS spasticity?

Nabiximols, a prescription spray containing equal parts THC and CBD, has the most clinical evidence for MS-related spasticity. Some patients report benefit, though trial results are mixed and effect sizes tend to be modest.

Why is there so little clinical evidence for cannabis in MS?

Most research has been done in animal models of demyelination rather than in people with MS. Regulatory barriers, variable cannabis formulations, and the difficulty of blinding participants in cannabis trials all contribute to the limited clinical data.

Read the original research

Cannabis and Cannabinoids in Multiple Sclerosis: From Experimental Models to Clinical Practice-A Review.

American journal of therapeutics, 30(3), e220-e231

View on PubMed ↗Publisher’s paper ↗

Citation

Sirbu, Carmen-Adella; Georgescu, Ruxandra; Pleşa, Florentina Cristina; Paunescu, Alina; Marilena Ţânţu, Monica; Nicolae, Alina Crenguţa; Caloianu, Ionut; Mitrica, Marian. (2023). Cannabis and Cannabinoids in Multiple Sclerosis: From Experimental Models to Clinical Practice-A Review.. American journal of therapeutics, 30(3), e220-e231. https://doi.org/10.1097/MJT.0000000000001568